Physician profile
Megan E Mason
NPI 1184887655
$5,040.63
in general payments reported to CMS, 2019-2025
52 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $37.31 · 2021: $359 · 2022: $1,009 · 2023: $1,005 · 2024: $1,129 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,294 · Education: $24.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,293.81 |
| Education | $24.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,253.47 | 2021-2025 | |
| Pfizer INC. | $373.80 | 2023-2025 | |
| Biogen, INC. | $316.14 | 2021-2024 | Vumerity, Avonex, Plegridy |
| Alexion Pharmaceuticals, INC. | $296.20 | 2019-2025 | Ultomiris, Soliris |
| Neurocrine Biosciences, INC. | $182.07 | 2019-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $172.82 | 2019-2025 | Mavenclad |
| Novo Nordisk INC | $145.19 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $141.16 | 2023-2025 | Rexulti |
| Argenx US, INC. | $128.33 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $124.72 | 2024-2025 | Amyvid, Kisunla, Emgality |
| Janssen Pharmaceuticals, INC | $121.42 | 2022 | |
| Novartis Pharmaceuticals Corporation | $119.17 | 2021-2025 | |
| Ucb, INC. | $105.75 | 2024-2025 | Rystiggo, Zilbrysq, Fintepla |
| Amgen INC. | $103.74 | 2019-2022 | |
| Catalyst Pharmaceuticals, INC. | $83.59 | 2022-2025 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.